Get started

LLY

LLY - Clean Levels UpdatedEli Lilly's hit those 708.49 and 711 levels I mentioned in my previous LLY post. I've added some weekly levels, and a couple relevant spots from my boxed LLY chart. If LLY loses steam up here we could easily see a retest of that box top area in the $680 - $678 range. Otherwise if we see a market wide reversion from today's liquidation, and LLY clears today's high(~714) and firmly holds that high volume area, that gap($738) fill would be a no-brainer. Personally leaning on the side of a short continuation(in the near time at least), didn't really trust the low volume float up over the last few trading days, and definitely don't like the decreasing volume into that $711 - $714 area (I'd consider it a Look above and fail). Regardless of bias, we trade what we see. ~ The Villain.
NYSE:LLYShort
by The_Villain_777
LLY - Clean LevelsBull flag patten on the LLY weekly Chart. The base of the flag/channel has been reactive so far although with low volume (See previously boxed LLY chart) off the top of the recent boxed range. If you look at the previous chart, you will see that LLY is currently floating up through a low volume node on the anchored volume profile. Unless sellers step in here, 708.49/709 - 711.44 is the next target. Volume will be in that area, if buyers step in, could be great for calls. Otherwise we could see a look above and fail of the top boxed range(again see previous chart under related publications to the right of this post). ~The Villain
NYSE:LLY
by The_Villain_777
LLY \$687.50 Call – One-Day High-Momentum Play🚀 LLY \$687.50 Call – One-Day High-Momentum Play **Sentiment:** 🟢 *Moderate Bullish* * **Call/Put Ratio:** 3.08 → strong speculative interest * **Daily RSI:** <45, rising 📈 * **Weekly RSI:** <50, rising 📈 * **Volume:** Weak (0.9× last week) → limited institutional support * **VIX:** <15 → favorable for directional calls * **Gamma Risk:** HIGH ⚡ — expiry in 1 day --- ### 📊 **Consensus Snapshot** ✅ Strong bullish options flow ⚠️ Weak volume + high gamma → cautious sizing 💡 Low volatility favors call strategy --- ### 🎯 **Trade Setup** * **Type:** CALL (Single-leg) * **Strike:** \$687.50 * **Expiry:** 2025-08-15 * **Entry:** \$0.79 * **Profit Target:** \$1.20 (+153%) * **Stop Loss:** \$0.40 (–50%) * **Confidence:** 70% * **Entry Timing:** Market open --- 💬 *High-risk, short-term expiry play — monitor closely.* 📌 *Not financial advice. DYOR.* --- **#LLY #OptionsTrading #CallOptions #DayTrading #StocksToWatch #GammaRisk #OptionsFlow #TradingSignals**
NYSE:LLYLong
by quantsignals
Eli Lilly (LLY) – Pharma Giant at a Key Price LevelHi, Eli Lilly & Co. is one of the world’s largest pharmaceutical companies, founded in 1876 and headquartered in Indianapolis. It operates in over 125 countries and is best known for blockbuster treatments in diabetes, obesity, oncology, and immunology. Recent growth has been driven largely by its GLP-1 class drugs Mounjaro and Zepbound, which have quickly become industry leaders in the weight-loss and diabetes markets. Recent Fundamentals (Q2 2025) Revenue: $15.56 B (+38% YoY) - EPS: $6.31 (beat expectations) - Mounjaro sales: $5.2 B - Zepbound sales: $3.38 B - Full-year guidance: Revenue $60–62 B, EPS $21.75–$23.00 - Margins: Gross margin ~82.6%, net margin ~25.9% - Profitability: ROE ~75.5%, ROIC ~29.6% While fundamentals remain strong, the recent Phase III data for the oral weight-loss pill orforglipron came in below expectations, sparking a ~14% drop, the stock’s steepest one-day decline in decades. Analysts have since trimmed long-term sales forecasts for this product. From a valuation perspective, the stock trades at a premium (~41× P/E, ~10.7× P/S), leaving little room for major disappointments. Technicals Technically speaking, the price has arrived in the zone where I’ve been patiently waiting to share it as an idea. This is a good area from where to start building positions if you’re interested. There are quite a few technical confluence factors aligning here, but be ready to grab it also around $500 if the market offers it. Let that be your guide: - If you’re not willing to hold long-term, don’t touch it. - If you’re not willing to buy more at lower prices, don’t touch it. Good luck, Vaido
NYSE:LLYLong
by VaidoVeek
ELI LILLY Is starting its next big rally.Eli Lilly (LLY) is about to test its 1W MA50 (blue trend-line) following a rebound just below the 1W MA100 (green trend-line). The latter, has been the ultimate market Support since May 2018 (last time it broke below it). The overall correction since the July 15 2024 High seems like a Bull Flag pattern, no different than all the others after 2018 which only served as healthy rebalancing of an overbought price action. Based on he 1W RSI in particular and the Bullish Divergence it displayed, the current Bull Flag resembles more the March - October 2019 pattern. Both that and the next one reached their 2.0 Fibonacci extensions. As a result, our long-term Target on LLY is just below the 2.0 Fib at $1300. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
2
Can Lilly Redefine Weight Loss Market Leadership?Eli Lilly is rapidly emerging as a dominant force in the burgeoning weight loss drug market, presenting a significant challenge to incumbent leader Novo Nordisk. Lilly has demonstrated remarkable commercial success despite its key therapy, Zepbound (tirzepatide), entering the market well after Novo Nordisk's Wegovy (semaglutide). Zepbound's substantial revenue in 2024 underscores its rapid adoption and strong competitive standing, leading market analysts to project Eli Lilly's obesity drug sales will surpass Novo Nordisk's within the next few years. This swift ascent highlights the impact of a highly effective product in a market with immense unmet demand. The success of Eli Lilly's tirzepatide, the active ingredient in both Zepbound and the diabetes treatment Mounjaro, stems from its dual mechanism targeting GLP-1 and GIP receptors, offering potentially enhanced clinical benefits. The company's market position was further solidified by a recent U.S. federal court ruling that upheld the FDA's decision to remove tirzepatide from the drug shortage list. This legal victory effectively halts compounding pharmacies from producing unauthorized, cheaper versions of Zepbound and Mounjaro, thereby protecting Lilly's market exclusivity and ensuring the integrity of the supply chain for the approved product. Looking ahead, Eli Lilly's pipeline includes the promising oral GLP-1 receptor agonist, orforglipron. Positive Phase 3 trial results indicate its potential as a convenient, non-injectable alternative with comparable efficacy to existing therapies. As a small molecule, orforglipron offers potential advantages in manufacturing scalability and cost, which could significantly expand access globally if approved. Eli Lilly is actively increasing its manufacturing capacity to meet anticipated demand for its incretin therapies, positioning itself to capitalize on the vast and growing global market for weight management solutions.
NYSE:LLYLong
by UDIS_View
Eli Lilly (LLY) Shares Fall Over 15% in MayEli Lilly (LLY) Shares Fall Over 15% in May The share price of Eli Lilly and Company (LLY), the world’s largest pharmaceutical company, has seen a sharp shift in market sentiment: → From its April low to high, LLY shares rose by over 30%; → However, since the start of May, the LLY stock price has dropped more than 15% — the closing price on the last trading day of April was around $895, while today the share is trading near $775. Why Are Eli Lilly (LLY) Shares Falling? The decline can be attributed to three key factors: 1→ Q1 Earnings Report: Although the company reported earnings per share above expectations ($3.34 vs $3.25), investors may have been concerned by significantly higher spending on research and development. 2→ Competitor Partnership: CVS Health’s announcement that it will offer Novo Nordisk’s Wegovy instead of Lilly’s Zepbound added further pressure to LLY shares. 3→ Sector Sentiment: Broader biotech sentiment turned negative following reports that the Trump administration is considering a pricing model that would cap drug prices based on lower rates in other countries. The media is also discussing upcoming decisions from Vinay Prasad, the new head of the FDA division overseeing vaccines and gene therapy. Technical Analysis: Eli Lilly (LLY) Share Chart Key price movements (marked on the chart) justify the formation of a downward channel. On the one hand, bearish sentiment may intensify in light of recent developments. The median line of the channel could act as resistance to any upward movement. On the other hand, bulls may find support around the $765 level — a former resistance point and the boundary between two price gaps. This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
NYSE:LLY
by FXOpen
Eli Lilly: Catch the Knife or Wait for Support?LLY Just Dropped — Opportunity or Trap? 🔥 LLY (Eli Lilly) is on every trader’s radar! With biotech momentum and blockbuster drug potential, this stock is ready to rip once the dust settles. Smart money is eyeing key zones for a golden entry. 💊📈 📉 New Entry Zones: 🔥 630.00 – Solid buy level 🔥 550.00 – Strong value zone 🔥 465.00 – Deep discount opportunity (load-up zone!) 🎯 Profit Targets: ✅ 730.00 📈 (First leg up) ✅ 800.00 🚀 (Breakout zone) ✅ 900.00+ 💰 (All-time high chase) 💡 Volatility creates opportunity. LLY is a beast in the pharma game—any dip could set up a powerful bounce. Watch for heavy accumulation and reversal signals near those buy zones! 🚀 Ready to ride the next wave? LLY’s runway is long and the upside is juicy! #LLY #PharmaStocks #BuyTheDip #GrowthPlays 📌 Disclaimer: Not financial advice. Do your own research and consult with a professional before investing. 🔎💼
NYSE:LLYLong
by Robert_V12
ELI LILLY: The time to buy and target 1,300 is now.Eli Lilly is neutral on its 1D technical outlook (RSI = 48.409, MACD = -5.160, ADX = 28.927) and this is technically the most efficient level to buy for the long term towards the end of the year, as the price is sitting around its 1W MA50. The macro pattern is a Channel Up starting back in March 2019 and every time this broke under the 1W MA50 (but remained supported above the 1W MA100) and consolidated, it was the most efficient long term buy signal. In 6 years this has only happened 4 times and all those times the 1W RSI hit the 38.750 S1 level. The immediate target of all bullish waves that started after such bottoms, has been the 2.0 Fibonacci extension. Go long, TP = 1,300. ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:LLYLong
by InvestingScope
The Next Big Healthcare Stock?The chart for VERV shows a prolonged downtrend since mid-2021, with multiple resistance trendlines capping price action. However, the stock is now testing a potential breakout above these trendlines and the 50-week EMA (green line), which has acted as dynamic resistance. The RSI is rising above 60, signaling increasing bullish momentum, and the latest weekly candle, up 11.28%, suggests growing buying interest. If VERV successfully holds above this breakout zone, it could push toward the $10-$15 resistance range, confirming a trend shift. However, failure to sustain above the 50EMA could result in another rejection, reinforcing the downtrend. Volume is picking up, adding weight to the bullish case, but confirmation above key levels remains crucial for a sustained move higher. Disclaimer: This analysis is for educational purposes only and should not be considered financial advice. Trading and investing involve risk, and independent research or consultation with a professional is recommended before making any financial decisions.
VLong
by MysticMads
ELI LILLY ahead of a 1D Golden Cross targeting $1225Last time we looked at Eli Lilly (LLY) 3 months ago (November 21 2024, see chart below), we've identified the bottom of its 5-year Channel Up and issued a strong long-term buy signal: Now we are upgrading our Target as the price action turned out to be very similar to the 2nd half of 2020, at the end of which the company witnessed strong growth. As you can see both 2020 and 2024 patterns have been correction phases in the form of Channel Downs. Even their 1D RSI sequences are similar. A 1D Death Cross paved the way for the bottom soon after and a 1D Golden Cross (Jan 11 2021) confirmed the start of a new phase of growth. The price is now above the 1D MA200 (orange trend-line) and if it continues to replicate 2021, then we expect this to be a Bullish Leg that will target the 1.786 Fibonacci extension. Our long-term Target now goes from $1135 to $1225. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
Halftime Report: LLY Up From Here? Hold for better PriceWe've been watching LLY after Open this morning allowed it to bounce up to $783.63. It has since settled on the 50% Retracement on the 5 Minute, which we were looking for it to break down back to at least the $765-$766 Price Range, looking to get in around $765.45specifically. With a Price Target $775 (Short-Term Trade Target) on the rebound and retest. We're looking at a stop around $761.97 to be safe in case it comes down hard and surpasses our entry. On a longer-time frame, we're looking for potential a $780.65 - $785 retest. Stay tuned by connecting at the website in our signature! We deliver this and more financial tools to make life that much easier on You! - @MyMIWallet #MyMIWallet
NYSE:LLYLong
by MyMIWallet
LLY 1H Swing Long Aggressive Trend TradeAggressive Trend Trade - short impulse + volumed TE / T1 + support level + biggest volume Sp + weak test + first bullish bar close entry Calculated affordable stop limit 1 to 2 R/R take profit Daily Context "+ long impulse + 1/2 correction - expanding T2 + support level + volumed manipulation" Monthly Context "+ long impulse + 1/2 correction + T2 level + support level - biggest volume manipulation" Yearly Context "+ long impulse - neutral zone"
NYSE:LLYLong
by MishaSuvorov
Why Buy LLY?A textbook spike trade... that's why! Every morning the stock market open gives us opening volatility spikes on the first 30 minute bar. Most are noise but when that rare one comes along that fits my rules AND has multiple matching confluences... it's time to "Strike at the Spike!" This setup has going for it: At a 50% Retracement of the recent trend (from November 18 - December 4) At the top of a Gap Level At the Volume Profile Point-of-Control for the last year of price action (see below) With a Spike that my indicator shows >80% ATR Clearance I consider the baseline for a trade; this one is 150% so it definitely fits the rules. I would take a spike if there were only 2 of those matching levels above. Targeting the local high for the first take profit at 834. Here is the Daily chart for just how key this level is: Full disclosure: NYSE:LLY is and has been one of my biggest holdings; having owned the stock for over a decade.
NYSE:LLYLong
by norok
Can Pharma Innovation Rewrite Healthcare's Future?In the rapidly evolving landscape of medical technology, Eli Lilly emerges as a beacon of transformative potential, challenging conventional boundaries of pharmaceutical innovation. With a strategic masterstroke, the company has positioned itself at the forefront of medical breakthroughs, particularly in the revolutionary realm of weight loss and diabetes treatments. The remarkable Zepbound medication stands as a testament to this vision, demonstrating unprecedented efficacy by enabling patients to lose an average of 20.2% body weight - a figure that not only surpasses competitors but also represents a paradigm shift in medical intervention. The company's financial architecture is equally compelling, reflecting a meticulously crafted approach to growth and shareholder value. With a staggering market capitalization of $722 billion, a 27.4% revenue growth, and an impressive 80.9% gross profit margin, Eli Lilly transcends the traditional pharmaceutical business model. Its recent $15 billion share buyback program and consistent 54-year dividend payment history underscore a strategic philosophy that balances aggressive innovation with prudent financial management, creating a blueprint for sustainable corporate success. Beyond financial metrics and breakthrough medications, Eli Lilly represents something more profound: a vision of healthcare's future where technology, research, and human potential converge. The company's $3 billion manufacturing expansion, commitment to oncology research with drugs like Jaypirca, and continuous investment in cutting-edge medical solutions paint a picture of an organization that sees beyond immediate profit - an entity committed to reshaping human health through relentless innovation and scientific excellence. In an era of unprecedented medical challenges, Eli Lilly stands not just as a pharmaceutical company, but as a harbinger of hope, demonstrating how visionary thinking can transform global health landscapes.
NYSE:LLYLong
by MorMedia
ELI LILLY has at least +50% upside from here.Eli Lilly (LLY) has been trading within a 5-year Channel Up and last week closed below its 1W MA50 (blue trend-line) for the first time since the week of March 06 2023. Despite the bearish pressure of this Bearish Leg since July 15 2024, that last 1W MA50 closing was the previous Higher Low at the bottom of the Channel Up. The 1W RSI is on a similar level (just below 40.00) with all previous 4 major bottoms and the common characteristic of all was that the stock broke below the 1W MA50 but managed to keep clear and hold the 1W MA100 (green trend-line), practically the most important Support level of the market. If you want a confirmed buy entry, you might want to wait for yet another Bullish Cross on the 1W MACD (as it happened on all previous bottoms), otherwise this buy opportunity is good to go for at least +58% from the bottom (minimum rise among those 4 Bullish Legs). Our Target is $1135. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
5
ELI LILLY: This consolidation is a buy opportunity.Eli Lilly is neutral on its 1D technical outlook (RSI = 52.880, MACD = 1.910, ADX = 25.797) as well as on 1W as for the past 7 weeks it has turned sideways. This consolidation is taking place half-way through the new bullish wave of the Channel Up that started in early 2023. As you see it is supported by the 1W MA50 and every bullish wave in the beginning was almost at +50% but the latest one was +35%. Consequently we expect a minimum of +46.22% from the bottom and that's what we're aiming for (TP = 1,095). See how our prior idea has worked out: ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:LLYLong
by InvestingScope